Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II).
Larry R Jackson IiPeter SchraderLaine ThomasBenjamin A SteinbergRosalia BlancoLarry A AllenGregg C FonarowJames V FreemanBernard J GershPeter R KoweyKenneth W MahaffeyGerald NaccarelliJames ReiffelDaniel E SingerEric D PetersonJonathan P Piccininull nullPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2021)
In routine clinical practice, prescribing of DOACs in patients with AF with moderate CKD is often inconsistent with drug labeling, with up to one-third of patients being inappropriately dosed.
Keyphrases
- clinical practice
- chronic kidney disease
- end stage renal disease
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- peritoneal dialysis
- ejection fraction
- high intensity
- primary care
- newly diagnosed
- adverse drug
- insulin resistance
- metabolic syndrome
- combination therapy
- skeletal muscle
- drug induced
- patient reported